Immunovaccine Inc. signs licensing deal with Pfizer to develop vaccine

Immunovaccine Inc. has announced that Pfizer Animal Health will exercise a licensing option on the company's vaccine enhancement and delivery platform to develop a third livestock vaccine.

This represents an important milestone for Immunovaccine as it further validates the potential of its vaccine platform, and enables the company to apply the upfront signing fees, and any milestone and royalty payments to further advance its vaccine pipeline.

Immunovaccine's patented vaccine enhancement platform uses liposomes in an oil depot to present antigens and adjuvants to the immune system. In preclinical models, the platform creates a depot effect that prolongs the immune system's exposure to the vaccine, resulting in a rapid, potent, and long lasting immune response after a single dose.

Meanwhile, the company is a clinical stage vaccine development company focused on the commercialisation of its vaccine technology and product candidates. Immunovaccine continues to strengthen its vaccine pipeline through licensing and strategic partnering to develop therapeutic cancer and infection disease vaccines.